

# LUNG CANCER **UPDATES**

**AACR HIGHLIGHTS**

**29 MARZO - 3 ABRIL 2019**



**ATLANTA**

Iniciativa científica de:



Grupo Español de Cáncer de Pulmón  
Spanish Lung Cancer Group



**LUNG CANCER**  
**UPDATES**  
**AACR HIGHLIGHTS**  
29 MARZO - 3 ABRIL 2019



ATLANTA

**Early signs of activity of Tedopi (OSE2101), a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors (ICI) Atlante-1 study trial**

Dr. Juan Felipe Córdoba


Iniciativa científica de:



Grupo Español de Cáncer de Pulmón  
Spanish Lung Cancer Group

# Early signs of activity of Tedopi (OSE2101), a multiple neoepitope vaccine, in a phase 3 trial in advanced lung cancer patients after failure to previous immune checkpoint inhibitors (ICI) Atlante-1 study trial


## ATLANTE-1: Phase 3 trial TEDOPI vs CT




After independent safety review in Nov 2017, only patients previously exposed to ICI were eligible as ICI become a SoC in 1st and 2d line NSCLC patients: all patients must have failed to ICI as last treatment before tedopi or control

## Patient 1 - Partial Response

Decrease of 41% in the sum of target lesions (from 39 mm to 23 mm)  
Progression Free Survival of 4.2 months and survival of 20.6+ months  
(FUp ongoing)



**Baseline Chest CT  
May 2017**



**On treatment after 5 injections of Tedopi  
August 2017**

# Case of interest - efficacy & safety

	Patient 1	Patient 2	Patient 3	Patient 4 (control)
Best response to Tedopi	<b>PR</b>	<b>SD &gt; 9 mo</b>	<b>SD &gt; 9 mo</b>	<b>PD</b>
Treatment duration	3.7 mo	11.5 mo	16.9 mo	<b>2.8 mo</b>
Progression Free Survival	4.2 mo	11 mo	18.1 mo	<b>2.1 mo</b>
OS after Tedopi initiation	20.6+ mo	22.1+ mo	20.3+ mo	<b>7.1+ mo</b>
Immune-related adverse events	No side effects	Post-injection Cytokine release syndrome x 5; Local site induration; Hyperthyroidism	Hyperthyroidism	<b>Hypothyroidism; Post-injection Fever x 2</b>
Treatment after Tedopi	Yes (CT)	Yes (CT)	Yes (CT)	<b>Yes (CT)</b>